Cart
sales@molnova.com
FIDAS-5
CAS No. 1391934-98-7
FIDAS-5( —— )
Catalog No. M22933 CAS No. 1391934-98-7
FIDAS-5 effectively competes against S-adenosylmethionine (SAM) for MAT2A binding.?FIDAS-5 has anticancer activities.?FIDAS-5 is a potent and orally active methionine S-adenosyltransferase 2A (MAT2A) inhibitor with an IC50 of 2.1 μM.FIDAS-5 induces the expression of cell cycle inhibitor, p21WAF1/CIP1. FIDAS-5 (3 μM; 36 h) treatment reduces the levels of both S-adenosylmethionine (SAM) and S-adenosylhomocysteine (SAH) in LS174T cells.FIDAS-5 (3 μM; 7 days; LS174T cells) treatment significantly inhibits the proliferation of LS174T cells.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 69 | In Stock |
|
| 5MG | 106 | In Stock |
|
| 10MG | 176 | In Stock |
|
| 25MG | 314 | In Stock |
|
| 50MG | 484 | In Stock |
|
| 100MG | 700 | In Stock |
|
| 500MG | 1341 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameFIDAS-5
-
NoteResearch use only, not for human use.
-
Brief DescriptionFIDAS-5 effectively competes against S-adenosylmethionine (SAM) for MAT2A binding.?FIDAS-5 has anticancer activities.?FIDAS-5 is a potent and orally active methionine S-adenosyltransferase 2A (MAT2A) inhibitor with an IC50 of 2.1 μM.FIDAS-5 induces the expression of cell cycle inhibitor, p21WAF1/CIP1. FIDAS-5 (3 μM; 36 h) treatment reduces the levels of both S-adenosylmethionine (SAM) and S-adenosylhomocysteine (SAH) in LS174T cells.FIDAS-5 (3 μM; 7 days; LS174T cells) treatment significantly inhibits the proliferation of LS174T cells.
-
DescriptionFIDAS-5 effectively competes against S-adenosylmethionine (SAM) for MAT2A binding.?FIDAS-5 has anticancer activities.?FIDAS-5 is a potent and orally active methionine S-adenosyltransferase 2A (MAT2A) inhibitor with an IC50 of 2.1 μM.FIDAS-5 induces the expression of cell cycle inhibitor, p21WAF1/CIP1. FIDAS-5 (3 μM; 36 h) treatment reduces the levels of both S-adenosylmethionine (SAM) and S-adenosylhomocysteine (SAH) in LS174T cells.FIDAS-5 (3 μM; 7 days; LS174T cells) treatment significantly inhibits the proliferation of LS174T cells. FIDAS-5 (3 μM) treatment inhibits the expression of c-Myc and cyclinD1 in LS174T CRC cells.?Mice are treated with FIDAS-5 (20 mg/kg) for 1 week.?The liver SAM levels are significantly reduced.FIDAS-5 (20 mg/kg; oral gavage; daily; for two weeks; athymic nude mice) treatment significantly inhibits the growth of xenograft tumors, with minimal difference in body weight.?
-
In VitroCell Viability Assay Cell Line:LS174T colorectal cancer (CRC) cells Concentration:3 μM Incubation Time:7 days Result:Significantly inhibited the proliferation of LS174T cells.
-
In VivoAnimal Model:16 athymic nude mice injected with HT29 CRC cellsDosage:20 mg/kg Administration:Oral gavage; daily; for two weeks Result:Significantly inhibited the growth of xenograft tumors.
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorMAT2A
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1391934-98-7
-
Formula Weight261.72
-
Molecular FormulaC15H13ClFN
-
Purity>98% (HPLC)
-
SolubilityDMSO:125 mg/mL (477.61 mM; Need ultrasonic)
-
SMILESCNC1=CC=C(/C=C/C2=C(F)C=CC=C2Cl)C=C1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Zhang W, et al. Fluorinated N,N-dialkylaminostilbenes repress colon cancer by targeting methionine S-adenosyltransferase 2A. ACS Chem Biol. 2013 Apr 19;8(4):796-803.
molnova catalog
related products
-
Toyocamycin
Toyocamycin is an adenosine analog produced by Actinomycete, acts as an XBP1 inhibitor, inhibits IRE1α-induced ATP-dependent XBP1 mRNA cleavage (IC50: 80 nM).
-
Benzyl benzoate
Benzyl benzoate is one of the older preparations used to treat scabies.
-
PGLa TFA (102068-15-...
PGLa TFA is a cationic antimicrobial peptide (AMP) originally isolated from frog. It has been shown to have antibacterial,antifungal,and antiviral,activities.
